drugset
Drugs / ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
last change Apr 2015 re-read 9 days ago

ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine

Vaccine

Developed for
fallopian tube cancer · malignant epithelial tumor of ovary · primary peritoneal carcinoma
Investigated by
National Cancer Institute (NCI) · Roswell Park Cancer Institute · Sanofi Pasteur, a Sanofi Company

Trials 1

today NCT01536054 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01536054 Aug 2012 → Apr 2015 fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma Roswell Park Cancer Institute Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536054 ↗
Modality Vaccine “ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine” NCT01536054 ↗
Route Subcutaneous “ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine subcutaneously (SC)” NCT01536054 ↗